These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11110054)

  • 21. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
    Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo.
    Ma Y; Zhao W; Li Y; Pan Y; Wang S; Zhu Y; Kong L; Guan Z; Wang J; Zhang L; Yang Z
    Biomaterials; 2019 Mar; 197():182-193. PubMed ID: 30660994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
    Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations.
    Meidan VM; Glezer J; Salomon S; Sidi Y; Barenholz Y; Cohen JS; Lilling G
    J Liposome Res; 2006; 16(1):27-43. PubMed ID: 16556548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.
    Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ
    Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
    Jiang H; Xia D; Wu LJ; Chen ZD
    Chin Med J (Engl); 2011 Dec; 124(23):4018-21. PubMed ID: 22340335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency.
    Lai JC; Brown BD; Voskresenskiy AM; Vonhoff S; Klussman S; Tan W; Colombini M; Weeratna R; Miller P; Benimetskaya L; Stein CA
    Mol Ther; 2007 Feb; 15(2):270-8. PubMed ID: 17235304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
    Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G
    Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
    Hu Q; Bally MB; Madden TD
    Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
    Wacheck V; Krepler C; Strommer S; Heere-Ress E; Klem R; Pehamberger H; Eichler HG; Jansen B
    Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
    Nichols GL; Stein CA
    Semin Oncol; 2003 Apr; 30(2):297-9. PubMed ID: 12720156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
    Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
    Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
    Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bcl-2 expression in cell lines breast cancer and death program.
    Janaghard MS; Soleimani S; Movafagh A; Motallebi M; Mousavi SA; Moghadam AAS; Moghadam VE; Khosravi A; Mirzaei HR; Mousavi SAR; Aziziaram Z; Sun C
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):277-285. PubMed ID: 38279418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
    Yoo BH; Bochkareva E; Bochkarev A; Mou TC; Gray DM
    Nucleic Acids Res; 2004; 32(6):2008-16. PubMed ID: 15064360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
    Yang X; Koh CG; Liu S; Pan X; Santhanam R; Yu B; Peng Y; Pang J; Golan S; Talmon Y; Jin Y; Muthusamy N; Byrd JC; Chan KK; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2009; 6(1):221-30. PubMed ID: 19183107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.